Biomedical Engineering Reference
In-Depth Information
30. El Haj AJ, Cartmell SH (2010) Bioreactors for bone tissue engineering. Proc Inst Mech Eng H
224(12):1523-1532
31. Ennis BW, Matrisian LM (1994) Matrix degrading metalloproteinases. J Neurooncol 18(2):
105-109
32. Fainardi E, Castellazzi M, Tamborino C, Trentini A, Manfrinato MC, Baldi E et al (2009)
Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active
matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple
sclerosis. Mult Scler 15(5):547-554
33. Freeman-Cook KD, Reiter LA, Noe MC, Antipas AS, Danley DE, Datta K et al (2007) Potent
selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett
17(23):6529-6534
34. Gailit J, Clark RA (1994) Wound repair in the context of extracellular matrix. Curr Opin Cell
Biol 6(5):717-725
35. Galvez BG, Genis L, Matias-Roman S, Oblander SA, Tryggvason K, Apte SS et al (2005)
Membrane type 1-matrix metalloproteinase is regulated by chemokines monocyte-chemoat-
tractant protein-1/ccl2 and interleukin-8/CXCL8 in endothelial cells during angiogenesis.
J Biol Chem 280(2):1292-1298
36. Gapski R, Barr JL, Sarment DP, Layher MG, Socransky SS, Giannobile WV (2004) Effect of
systemic matrix metalloproteinase inhibition on periodontal wound repair: a proof of concept
trial. J Periodontol 75(3):441-452
37. Gapski R, Hasturk H, Van Dyke TE, Oringer RJ, Wang S, Braun TM et al (2009) Systemic
MMP inhibition for periodontal wound repair: results of a multi-centre randomized-controlled
clinical trial. J Clin Periodontol 36(2):149-156
38. Geisler S, Lichtinghagen R, Boker KH, Veh RW (1997) Differential distribution of five mem-
bers of the matrix metalloproteinase family and one inhibitor (TIMP-1) in human liver and
skin. Cell Tissue Res 289(1):173-183
39. Giaccone G, Soria J-C (2007) Targeted therapies in oncology. Informa Healthcare, New York
40. Goffin JR, Anderson IC, Supko JG, Eder JP Jr, Shapiro GI, Lynch TJ et al (2005) Phase I trial
of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel
in patients with advanced non-small cell lung cancer. Clin Cancer Res 11(9):3417-3424
41. Gramoun A, Goto T, Nordstrom T, Rotstein OD, Grinstein S, Heersche JN et al (2010) Bone
matrix proteins and extracellular acidification: potential co-regulators of osteoclast morphol-
ogy. J Cell Biochem 111(2):350-361
42. Grassi F, Cristino S, Toneguzzi S, Piacentini A, Facchini A, Lisignoli G (2004) CXCL12
chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12
levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol
199(2):244-251
43. Greenwald RA, Zucker S, Golub LM (1999) Inhibition of matrix metalloproteinases:
therapeutic applications. New York Academy of Sciences, New York, NY
44. Gristina AG (1994) Implant failure and the immuno-incompetent fi bro-in fl ammatory zone.
Clin Orthop Relat Res (298):106-118
45. Gruber HE, Ingram JA, Hoelscher GL, Zinchenko N, Norton HJ, Hanley EN Jr (2009) Matrix
metalloproteinase 28 a novel matrix metalloproteinase is constitutively expressed in human
intervertebral disc tissue and is present in matrix of more degenerated discs. Arthritis Res Ther
11(6):R184
46. Gu Q, Wang D, Gao Y, Zhou J, Peng R, Cui Y et al (2002) Expression of MMP1 in surgical
and radiation-impaired wound healing and its effects on the healing process. J Environ Pathol
Toxicol Oncol 21(1):71-78
47. Hay ED (1991) Cell biology of extracellular matrix, 2nd edn. Plenum, New York
48. He H, Puerta DT, Cohen SM, Rodgers KR (2005) Structural and spectroscopic study of reac-
tions between chelating zinc-binding groups and mimics of the matrix metalloproteinase and
disintegrin metalloprotease catalytic sites: the coordination chemistry of metalloprotease inhi-
bition. Inorg Chem 44(21):7431-7442
Search WWH ::
Custom Search